Samchundang Pharmaceutical (000250.KS) FY2025: Ailia Biosimilar Debut Drives 220% Operating Profit Surge, Swings to Net Profit
Canada's first commercial Ailia biosimilar shipments lifted Samchundang to a three-year profit recovery, but the decisive volume ramp — and the test of this thesis — arrives only in 2026 when European and U.S. markets open.
Source: Annual Report (사업보고서) — Filed March 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions
“Samchundang Pharmaceutical (000250.KS) FY2025: Ailia Biosimilar Debut Drives 220% Operating Profit Surge, Swings to Net Profit”
This article became available on July 24, 2026. Subscribe to read in full, or wait until October 22, 2026 when it becomes free.
Cancel anytime. Full refund within 7 days.
You just read what happened. Here's how to read what it means.
LineVest Daily lands in your inbox before every Seoul open: the key KOSPI & KOSDAQ stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.
We read Samchundang Pharmaceutical's latest DART filing in full — financials under K-IFRS, governance, and what it means for the stock. PDF in your inbox within 3 hours.
$12 · one-time
Get the Samchundang Pharmaceutical reportReading several Korean stocks a week? Read every analysis article the moment it publishes — full daily KOSPI & KOSDAQ coverage plus the 90-day archive.
$9.99 · monthly
SubscribeIndependent journalism based on primary DART filings — not investment advice. No brokerage affiliation.
